# Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

> **NCT01884441** · PHASE2 · UNKNOWN · sponsor: **Armando Santoro, MD** · enrollment: 59 (estimated)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01884441
- **Lead sponsor:** Armando Santoro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07
- **Primary completion:** 2014-07
- **Final completion:** 2016-07
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884441, "Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01884441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*